Kamada Ltd. (NASDAQ:KMDA) Short Interest Update

Kamada Ltd. (NASDAQ:KMDA) saw a significant drop in short interest in the month of February. As of February 28th, there was short interest totalling 35,100 shares, a drop of 78.9% from the February 13th total of 166,100 shares. Based on an average trading volume of 194,200 shares, the days-to-cover ratio is currently 0.2 days. Currently, 0.1% of the company’s shares are sold short.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a “buy” rating and set a $11.00 price objective on shares of Kamada in a research report on Thursday, March 6th.

Institutional Investors Weigh In On Kamada

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. NewEdge Advisors LLC lifted its position in Kamada by 54.2% during the fourth quarter. NewEdge Advisors LLC now owns 23,496 shares of the biotechnology company’s stock valued at $143,000 after buying an additional 8,260 shares during the period. Aristides Capital LLC lifted its position in Kamada by 12.1% during the 4th quarter. Aristides Capital LLC now owns 63,485 shares of the biotechnology company’s stock valued at $387,000 after acquiring an additional 6,850 shares during the period. Geode Capital Management LLC boosted its stake in Kamada by 5.6% during the fourth quarter. Geode Capital Management LLC now owns 29,289 shares of the biotechnology company’s stock worth $178,000 after acquiring an additional 1,549 shares in the last quarter. JPMorgan Chase & Co. bought a new stake in Kamada during the fourth quarter worth about $67,000. Finally, Public Employees Retirement System of Ohio purchased a new stake in Kamada in the third quarter worth about $77,000. 20.38% of the stock is owned by hedge funds and other institutional investors.

Kamada Price Performance

KMDA traded down $0.11 on Thursday, hitting $7.23. The company had a trading volume of 57,896 shares, compared to its average volume of 255,067. The stock has a fifty day simple moving average of $7.20 and a 200-day simple moving average of $6.20. The firm has a market capitalization of $415.58 million, a P/E ratio of 25.82, a P/E/G ratio of 0.97 and a beta of 0.97. Kamada has a 52-week low of $4.74 and a 52-week high of $9.15.

Kamada Announces Dividend

The company also recently announced a — dividend, which will be paid on Monday, April 7th. Stockholders of record on Monday, March 17th will be paid a $0.20 dividend. The ex-dividend date is Monday, March 17th.

Kamada Company Profile

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.